# EDGAR Filing Document

**Accession Number:** 0001636651
**File Stem:** 0001839882-23-003736
**Filing Date:** 2023-2
**Character Count:** 6967
**Document Hash:** a37d7e34eae0dc845cca42f71f61cc7d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001839882-23-003736.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001839882-23-003736

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ovid Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001636651
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 465270895
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90350
- **FILM NUMBER:** 23628491

**BUSINESS ADDRESS:**
- **STREET 1:** 1460 BROADWAY
- **STREET 2:** SUITE 15044
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 212-776-4381

**MAIL ADDRESS:**
- **STREET 1:** 1460 BROADWAY
- **STREET 2:** SUITE 15044
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEVIN JEREMY M
- **CENTRAL INDEX KEY:** 0001256153

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 13G/A**

**(Amendment No. 4)** 

**Under the Securities Exchange Act of 1934** 

**OVID THERAPEUTICS INC.** 

**(Name of Issuer)** 

**COMMON STOCK, $0.001 PAR VALUE** 

**(Title of Class of Securities)** 

**690469101** 

**(CUSIP Number)** 

**DECEMBER 31, 2022**

**(Date of Event Which Requires Filing of This Statement)** 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b) <br> ☐ Rule 13d-1(c) <br> ☒ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

<br> CUSIP No. 690469101 Page 2 of 5 Pages

1. Name of Reporting
 Persons Jeremy
 M. Levin

2. Check the
 Appropriate Box if a Member of a Group (See Instructions) (a) ☐
 (b) ☒

3. SEC
 USE ONLY

4. Citizenship
 or Place of Organization United
 States of America

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 5. | Sole Voting Power<br> 7,281,121 (1) |
| &nbsp;&nbsp;&nbsp;Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 6. | Shared Voting Power<br> 0 |
| &nbsp;&nbsp;&nbsp;Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 7. | Sole Dispositive Power<br> 7,281,121 (1) |
| &nbsp;&nbsp;&nbsp;Number of<br> Shares<br> Beneficially<br> Owned by<br> Each<br> Reporting<br> Person<br> With: | 8. | Shared Dispositive Power<br> 0 |

---

9. Aggregate
 Amount Beneficially Owned by Each Reporting Person 7,281,121
 (1)

10. Check if
 the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

11. Percent of
 Class Represented by Amount in Row (9) 10.0%
 (2)

12. Type of Reporting
 Person (See Instructions) IN

(1) Consists of (i) 4,736,529 shares of the Issuer's common stock held directly by the Reporting Person, (ii) 35,461 shares held by Divo Holdings, LLC, a limited liability company managed by the Reporting Person's spouse, and (iii) 2,509,131 shares of common stock issuable upon the exercise of stock options within 60 days of
December 31, 2022.

(2) This percentage is calculated based upon 70,466,885 outstanding shares of the Issuer's common stock, as reported in the Issuer's Form 10-Q Quarterly Report (Commission File No. 001-38085) filed with the Securities and Exchange Commission on November 8, 2022.

<br> CUSIP No. 690469101 Page 3 of 5 Pages

<u>Item 1(a)</u> <u>Name of Issuer</u>

Ovid Therapeutics Inc.

<u>Item 1(b)</u> <u>Address of Issuer's Principal Executive Offices</u>

441 Ninth Avenue, 14th Floor

New York, New York 10001

<u>Item 2(a)</u> <u>Name of Person Filing</u>

Jeremy M. Levin

<u>Item 2(b)</u> <u>Address of Principal Business Office or, if none, Residence</u>

c/o Ovid Therapeutics Inc.

441 Ninth Avenue, 14th Floor

New York, New York 10001

<u>Item 2(c)</u> <u>Citizenship</u>

United States of America

<u>Item 2(d)</u> <u>Title of Class of Securities</u>

Common Stock, $0.001 par value

<u>Item 2(e)</u> <u>CUSIP Number</u>

690469101

<u>Item 3</u>

Not applicable.

<u>Item 4</u> <u>Ownership</u>

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

(a) Amount
beneficially owned: See Row 9 of cover page for each Reporting Person

(b) Percent
of class: See Row 11 of cover page for each Reporting Person

(c) Number
of shares as to which the person has:

&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole
power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared
power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole
power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared
power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

---

| | |
|:---|:---|
| <u>Item 5</u> | <u>Ownership of Five Percent or Less of a Class</u> |

---

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

---

| | |
|:---|:---|
| <u>Item 6</u> | <u>Ownership of More than Five Percent of Another Person</u> |

---

Not applicable.

CUSIP No. 690469101 Page 4 of 5 Pages

<br> <u>Item 7</u> <u>Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company</u>

Not applicable.

<u>Item 8</u> <u>Identification and Classification of Members of the Group</u>

Not applicable.

<u>Item 9</u> <u>Notice of Dissolution of Group</u>

Not applicable.

<u>Item 10</u> <u>Certification</u>

Not applicable.

CUSIP No. 690469101 Page 5 of 5 Pages

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023.

---

| | |
|:---|:---|
| By: | /s/ Jeremy M. Levin |
|  | Jeremy M. Levin |

---